Skip to main content
Top
Published in: International Urology and Nephrology 9/2015

01-09-2015 | Urology - Original Paper

Non-neoplastic parenchymal changes in kidney cancer and post-partial nephrectomy recovery of renal function

Authors: Wassim M. Bazzi, Ling Y. Chen, Billy H. Cordon, Joseph Mashni, Daniel D. Sjoberg, Melanie Bernstein, Paul Russo

Published in: International Urology and Nephrology | Issue 9/2015

Login to get access

Abstract

Objective

To explore the association of non-neoplastic parenchymal changes (nNPC) with patients’ health and renal function recovery after partial nephrectomy (PN).

Materials and methods

This retrospective review identified 800 pT1a patients who underwent PN at Memorial Sloan Kettering Cancer Center from 2007 to 2012. Pathology reports were reviewed for nNPC graded as mild or severe: vascular sclerosis (VS), glomerulosclerosis (GS), and fibrosis/scarring. Correlations between nNPC and known preoperative predictors of renal function [age, sex, African-American race, estimated glomerular filtration rate (eGFR), American Society of Anesthesiologists (ASA) score, body mass index, coronary artery disease, and hypertension (HTN)] were assessed using Spearman’s rank correlation (ρ). Multivariable linear regression, adjusted for the described known preoperative risk predictors, was performed to evaluate whether the parenchymal features were able to predict 6-month postoperative eGFR.

Results

In this study, 46 % of tumors had benign surrounding parenchyma. We noted statistically significant yet weak associations of VS with age (ρ = 0.19; p < 0.001), ASA (ρ = 0.09; p < 0.001), preoperative eGFR (ρ = −0.14; p < 0.001), and HTN (ρ = 0.14; p < 0.001). GS also significantly correlated with HTN, but the correlation was again small (ρ = 0.12; p < 0.001). After adjusting for known risk predictors, only GS was a significant predictor of 6-month postoperative eGFR. When compared with no GS, mild and severe GS were negatively associated with a decrease of 4.9 and 10.8 mL/min/1.73 m2 in 6-month postoperative eGFR, respectively.

Conclusions

Presence of VS and GS correlated with patients’ baseline health, and presence of GS predicted postoperative renal function recovery.
Literature
1.
go back to reference Stengel B (2010) Chronic kidney disease and cancer: a troubling connection. J Nephrol 23:253–262PubMed Stengel B (2010) Chronic kidney disease and cancer: a troubling connection. J Nephrol 23:253–262PubMed
3.
go back to reference Russo P (2013) Oncological and renal medical importance of kidney-sparing surgery. Nat Rev Urol 10:292–299CrossRefPubMed Russo P (2013) Oncological and renal medical importance of kidney-sparing surgery. Nat Rev Urol 10:292–299CrossRefPubMed
4.
go back to reference Bijol V, Mendez GP, Hurwitz S et al (2006) Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens predicting the risk of progressive renal failure. Am J Surg Pathol 30:575–584CrossRefPubMed Bijol V, Mendez GP, Hurwitz S et al (2006) Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens predicting the risk of progressive renal failure. Am J Surg Pathol 30:575–584CrossRefPubMed
5.
go back to reference Henriksen KJ, Meehan SM, Chang A (2009) Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med 133:1012–1025PubMed Henriksen KJ, Meehan SM, Chang A (2009) Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med 133:1012–1025PubMed
6.
go back to reference Salvatore SP, Cha EK, Rosoff JS et al (2013) Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function. Arch Pathol Lab Med 137:531–540CrossRefPubMed Salvatore SP, Cha EK, Rosoff JS et al (2013) Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function. Arch Pathol Lab Med 137:531–540CrossRefPubMed
7.
go back to reference Bonsib SM, Pei Y (2010) The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important? Adv Anat Pathol 17:235–250CrossRefPubMed Bonsib SM, Pei Y (2010) The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important? Adv Anat Pathol 17:235–250CrossRefPubMed
8.
go back to reference Truong LD, Shen SS, Park M-H et al (2009) Diagnosing nonneoplastic lesions in nephrectomy specimens. Arch Pathol Lab Med 133:189–200PubMed Truong LD, Shen SS, Park M-H et al (2009) Diagnosing nonneoplastic lesions in nephrectomy specimens. Arch Pathol Lab Med 133:189–200PubMed
9.
go back to reference Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York
10.
go back to reference Donin NM, Suh LK, Barlow L et al (2012) Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma. BJU Int 109:379–383CrossRefPubMed Donin NM, Suh LK, Barlow L et al (2012) Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma. BJU Int 109:379–383CrossRefPubMed
12.
go back to reference Dripps RD, Lamont A, Eckenhoff JE (1961) The role of anesthesia in surgical mortality. JAMA 178:261–266CrossRefPubMed Dripps RD, Lamont A, Eckenhoff JE (1961) The role of anesthesia in surgical mortality. JAMA 178:261–266CrossRefPubMed
13.
go back to reference Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663CrossRefPubMed Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663CrossRefPubMed
14.
go back to reference Ohno Y, Nakashima J, Ohori M et al (2011) Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma. J Urol 186:1242–1246CrossRefPubMed Ohno Y, Nakashima J, Ohori M et al (2011) Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma. J Urol 186:1242–1246CrossRefPubMed
15.
go back to reference Lang EK, Earhart V, Atug F et al (2007) Slow progressive loss of renal function due to arteriovenous fistula caused by renal biopsy. J Urol 177:735CrossRefPubMed Lang EK, Earhart V, Atug F et al (2007) Slow progressive loss of renal function due to arteriovenous fistula caused by renal biopsy. J Urol 177:735CrossRefPubMed
16.
go back to reference Rule AD, Cornell D, Poggio ED (2011) Senile nephrosclerosis—does it explain the decline in glomerular filtration rate with aging? Nephron Physiol 119:6–11CrossRef Rule AD, Cornell D, Poggio ED (2011) Senile nephrosclerosis—does it explain the decline in glomerular filtration rate with aging? Nephron Physiol 119:6–11CrossRef
Metadata
Title
Non-neoplastic parenchymal changes in kidney cancer and post-partial nephrectomy recovery of renal function
Authors
Wassim M. Bazzi
Ling Y. Chen
Billy H. Cordon
Joseph Mashni
Daniel D. Sjoberg
Melanie Bernstein
Paul Russo
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 9/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1066-1

Other articles of this Issue 9/2015

International Urology and Nephrology 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine